Improved outcomes for COVID-19 patients on ventilators | Azithromycin & CV mortality | Ertugliflozin & type 2 diabetes

Why dexamethasone could be a legitimate game-changer in the fight against COVID-19—and an update on the FDA and hydroxychloroquine.

Outpatient prescriptions for azithromycin are associated with an increased risk of cardiovascular mortality, according to new research published in JAMA Network Open.

The VERTIS CV Study tracked the performance of ertugliflozin and a placebo in more than 8,000 adult T2D patients.

Researchers have found a link between myocardial injury and a higher risk of death among patients hospitalized in the United States for COVID-19.

So what, exactly, occurs inside the human heart during a myocardial infarction?

A cardiologist at the University of Chicago Medicine has performed the first cardioneural ablation in U.S. history, using it to “rewire” the heart of a patient suffering from vasovagal syncope.

An inquest into the death of a 24-year-old scaffolder has found that the patient was “failed” by his healthcare providers.

The FDA has cleared an AI startup based in Israel to market its predictive-analytics product to ICUs during the present pandemic.